Cardiogen is sold here for laboratory research, in 1 size (20mg), starting at $85.00 a vial. Every batch arrives with a certificate naming the test that identified it, the test that measured its purity, and the date each was run. It is not an FDA-approved medicine. Research use only, and never for people or animals.
Cardiogen specifications
| Product name | Cardiogen |
|---|---|
| Physical form | Freeze-dried powder — a solid cake in a sealed vial |
| Appearance | White to off-white cake |
| Sizes on this page | 20mg |
| Purity specification | ≥99% by RP-HPLC. The number for the lot you receive is whatever its own certificate says. |
| Identity check | Mass spectrometry, read against the mass this compound should have |
| Net content | Weighed per lot and reported separately from purity |
| Lot documentation | At the laboratory — each certificate posts here the day it clears |
| Storage | Sealed, cold and out of the light |
| Ships from | Santa Ana, California — same business day on verified in-stock orders placed before 12 PM Pacific |
| Intended use | Laboratory research only. Not for human or animal use. |
What is Cardiogen, and what does it do?
Supplier lists write it as peptide Cardiogen; every one of those is this record, and the lot certificate further down counts for more than the wording on a label.
Short synthetic peptide from the Khavinson "bioregulator" series.
Mechanism is not established in the conventional receptor sense. The originating group proposes that these peptides act epigenetically, entering cells and binding directly to specific DNA sequences to modulate transcription of tissue-relevant genes, with molecular docking used as the supporting method. That is a hypothesis about a mechanism, not a demonstrated pathway, and it has not been independently confirmed outside the groups that advanced it.
Appears in a preclinical literature of organotypic tissue culture, rodent models and gene-expression work, largely produced by the St Petersburg Institute of Bioregulation and Gerontology and collaborating Russian institutes. A substantial share is published in Russian, in journals with limited international circulation.
No approved product outside Russia, no pharmacopoeial monograph, no independently replicated mechanism, and no controlled trial meeting United States or European standards. The volume of commercial writing about this series greatly exceeds what its cited sources report.
Cardiogen for sale: 20mg vials, price per mg
Cardiogen is sold in 1 size here, 20mg, from $85.00 a vial. The per-mg column is the honest comparison between sizes; the two tier columns show what ten and twenty vials of one size bill at, because the volume discount is per size and mixed sizes do not combine.
| Size | One vial | Per mg | 10 vials −10% | 20 vials −15% | Availability |
|---|---|---|---|---|---|
| Cardiogen 20mg | $85.00 | $4.25 | $765.00$3.83/mg | $1,445.00$3.61/mg | Backordered — waitlist |
Cardiogen discounts: bulk pricing, Subscribe & Save, and codes
Three things move this price and nothing else does: how many vials of one size are on the order, whether that order repeats, and one code. The fourth column prices each route against the 20mg vial.
| Buying option | Takes off | When it applies | 20mg at this option |
|---|---|---|---|
| One vial, one time | — | Any order | $85.00 |
| 10–19 vials of one size | 10% | This order | $765.00$76.50 a vial |
| 20 vials of one size | 15% | This order | $1,445.00$72.25 a vial |
| Subscribe, every 1 month | 6% | Shipment 2 onward | First $85.00, then $79.90 |
| Subscribe, every 2 months | 4% | Shipment 2 onward | First $85.00, then $81.60 |
| Subscribe, every 3 months | 2% | Shipment 2 onward | First $85.00, then $83.30 |
| 10 vials on a monthly subscription | 10%, then 6% more | Shipment 2 onward | First $765.00, then $719.10 |
| Sign-up code | 10% of the order | One use, dead 24 hours after signup | $76.50 for one vial |
| Friday newsletter code | 5% of the order | Live 24 hours, a new one each Friday | $80.75 for one vial |
| On-site offer code | 5% of the order | Live 30 minutes from when it appears | $80.75 for one vial |
| Free standard shipping | The shipping charge | Orders over $200 | 3 vials |
The first three stack; the codes do not. A volume discount comes off the line, a subscription cadence comes off that same line from shipment 2, and one code comes off what is left. One code per order, never two. A subscription runs a minimum of two shipments and can be cancelled once the second has shipped, and the first shipment always bills at today's eligible price with no cadence discount on it. The lowest this record ever bills is $3.40 per mg: twenty 20mg vials on a monthly subscription, from shipment 2 onward.
Every figure above is what you pay; nothing is added at checkout — dispatch and delivery work the same on every order.
Where to buy Cardiogen: five checks before you order from anyone
You can buy Cardiogen online here with guest checkout; verified in-stock orders placed before 12 PM Pacific are dispatched the same day.
Run these on us too. A supplier who cannot pass them is asking you to take their word for it, and their word is the one thing a certificate exists to replace.
- Check the certificate on the lab’s own site, not ours.
- See whether it was written for the seller.
- Match the lot number on the paper to the one on the vial.
- Look for a method and a date next to every number.
- Make sure identity was tested, not assumed.
Each of those is worked through, with what a failed check actually looks like, on verifying a certificate.
The Cardiogen certificate: lot, purity, identity, and how to verify it
A certificate answers identity, purity and net content as three separate questions, each with the method that produced it and the date it was run — how to read one covers what each field does and does not cover.
The certificate below belongs to one lot, and its number matches the one printed on the vial you receive. A real report for a different batch is still the wrong report.
| Size | Lot | Identity method | Purity | Test date |
|---|---|---|---|---|
| 20mg | Pending verification | Pending verification | Pending verification | Pending verification |
No lot documentation is published for Cardiogen yet. Rather than display a placeholder certificate, this record shows the gap until each field has been verified against the lot in hand. The certificate index lists every lot the moment its report clears.
Solution arithmetic for the bench, with no administration guidance: the vial concentration calculator, preset to Cardiogen.
Where the FDA stands on Cardiogen
The FDA has not approved this compound for anything, and nothing in this catalogue is a medicine. Where a compound stands legally depends on what it is, what form it is in, what it is being used for and which country you are in, and it changes over time, so the status shown here carries the date it was last checked.
Status verified 2026-08-25. Regulatory positions move; check the primary source before relying on any summary, including this one.
It is sold here as laboratory material under the research-use restriction that closes this page, which is not an approval, and not a statement that the compound is safe, effective or right for any purpose.
Cardiogen research: what the published studies examine
Status: No FDA-approved application. This compound is sold as laboratory material. Where research on it has been published, it sits at the animal, cell or early-human stage, and this record does not summarise what it found. A supplier is not a neutral judge of evidence about its own catalogue.
Cardiogen is the heart-associated member of the series. Vendor material commonly gives a specific tetrapeptide sequence for it; that assignment is not confirmable from the indexed literature, and unlike Cortagen, Cartalax, Vesugen and Pinealon it has no PubMed concept mapping to a named sequence. The page therefore does not state one. The originating group proposes that these peptides act epigenetically, entering cells and binding directly to specific DNA sequences to modulate transcription of tissue-relevant genes, with molecular docking used as the supporting method.
That is a hypothesis about a mechanism, not a demonstrated pathway, and it has not been independently confirmed outside the groups that advanced it. The series was developed at the St Petersburg Institute of Bioregulation and Gerontology, and the design premise is tissue specificity: each short peptide is claimed to act on the organ its parent extract came from. That premise rests principally on explant-outgrowth assays from the same group.
| Reported observation | Model | Source |
|---|---|---|
| Synthetic peptides cardiogen, bronchogen, prostamax and pancragen were applied to organotypic explant cultures from heart, lung, prostate and pancreas of young (3-week) and aged (18-month) rats. At 0.05 ng/ml each stimulated explant outgrowth in its corresponding tissue relative to control across all groups — the tissue-specificity claim the series is built on. | organotypic explant culture, young and aged rat tissue | Zakutskii and colleagues, The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissue culture in young and old rats, Advances in Gerontology (2006)Published in Russian with an English abstract. Explant outgrowth in culture is a long way from a tissue effect in an animal. |
| The originating review sets out the peptide theory of ageing and the design principle behind the series: dipeptides specific for thymus and tetrapeptides specific for heart, liver, brain cortex and pineal gland stimulate outgrowth of explants from their corresponding organs. It reports lifespan extension in rats, mice and fruit flies for the pineal preparations. | review of three decades of the originating group's own work | Khavinson, Peptides and Ageing, Neuroendocrinology Letters (2002)A 134-page supplement authored by the series originator reviewing his own institute's work. Foundational for the field and not an independent appraisal of it. |
Open questions. The indexed literature specific to Cardiogen is extremely thin — it appears principally as one arm of multi-peptide explant-culture comparisons rather than as the subject of its own studies, and its sequence cannot be confirmed from those sources. Two limitations apply to every compound in this series and are worth stating plainly rather than once at the bottom of a catalogue. First, provenance: the great majority of primary work comes from one institute and its collaborators, much of it published in Russian, and independent replication outside that network is scarce.
That is a limit on how confidently the findings can be read, not an allegation about them. Second, the assays: explant outgrowth in organotypic culture and gene-expression shifts in cultured cells are the dominant endpoints, and neither establishes what a compound does in an intact animal, let alone a person. The proposed epigenetic mechanism — short peptides entering the nucleus and binding DNA directly — is supported largely by molecular docking, which is a computational prediction rather than a measurement.
Each row above describes an observation in the stated model. None of it describes what Cardiogen would do in a person or an animal outside that model, and none of it is a recommendation to use it for anything.
Questions about Cardiogen
Where to buy Cardiogen Peptide, and can I get it online?
How much does Cardiogen Peptide cost?
What is the cheapest way to buy Cardiogen Peptide?
What is Cardiogen used for?
How does Cardiogen work, and what does it do?
What does Cardiogen peptide do?
What is Cardiogen peptide?
How do I verify the certificate of analysis is real?
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
